Outlook Therapeutics, Inc. SEC filings OTLK
Outlook Therapeutics, Inc. has 833 filings in SEC EDGAR's recent list, going back to Aug 10, 2015. Its latest annual report, Form ARS, was filed on Jan 26, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 18, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (listing notice). The company's fiscal year ends on September 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-Q | Filing | Aug 17, 2026 | Jun 30, 2026 |
| EFFECT | Filing | Jul 21, 2026 | — |
| DRS | Filing | Jul 8, 2026 | — |
| D | Filing | May 7, 2026 | — |
| EFFECT | Filing | Mar 28, 2025 | — |
| CORRESP | Letter to the SEC | Mar 26, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 26, 2025 | — |
| EFFECT | Filing | Mar 7, 2025 | — |
| CORRESP | Letter to the SEC | Mar 5, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2025 | — |
| D | Filing | Jan 27, 2025 | — |
| EFFECT | Filing | May 6, 2024 | — |
| CORRESP | Letter to the SEC | May 2, 2024 | — |
| UPLOAD | Letter from the SEC | May 1, 2024 | — |
| D | Filing | Apr 16, 2024 | — |
| EFFECT | Filing | Apr 5, 2024 | — |
| CORRESP | Letter to the SEC | Apr 3, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2024 | — |
| EFFECT | Filing | Apr 1, 2024 | — |
| D | Filing | Mar 29, 2024 | — |
| CORRESP | Letter to the SEC | Mar 28, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 28, 2024 | — |
| EFFECT | Filing | Aug 25, 2023 | — |
| CORRESP | Letter to the SEC | Aug 23, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2023 | — |
| D | Filing | Jan 6, 2023 | — |
| D | Filing | Jan 6, 2023 | — |
| 25-NSE | Delisting notice | Feb 16, 2022 | — |
| EFFECT | Filing | Apr 1, 2021 | — |
| CORRESP | Letter to the SEC | Apr 1, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2021 | — |
| D | Filing | Feb 12, 2021 | — |
| D | Filing | Jun 9, 2020 | — |
| EFFECT | Filing | Apr 17, 2020 | — |
| CORRESP | Letter to the SEC | Apr 16, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2020 | — |
| D | Filing | Mar 11, 2020 | — |
| EFFECT | Filing | Jun 26, 2019 | — |
| CORRESP | Letter to the SEC | Jun 24, 2019 | — |
| CORRESP | Letter to the SEC | Jun 21, 2019 | — |
| POS EX | Filing | Apr 10, 2019 | — |
| EFFECT | Filing | Apr 9, 2019 | — |
| CORRESP | Letter to the SEC | Apr 9, 2019 | — |
| CORRESP | Letter to the SEC | Apr 9, 2019 | — |
| CORRESP | Letter to the SEC | Apr 5, 2019 | — |
| CORRESP | Letter to the SEC | Apr 2, 2019 | — |
| CORRESP | Letter to the SEC | Apr 2, 2019 | — |
| EFFECT | Filing | Feb 27, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 27, 2019 | — |
| CT ORDER | Filing | Feb 26, 2019 | — |
| SEC STAFF ACTION | Filing | Feb 22, 2019 | — |
| 25-NSE | Delisting notice | May 16, 2018 | — |
| EFFECT | Filing | Mar 30, 2018 | — |
| EFFECT | Filing | Feb 28, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 27, 2018 | — |
| CORRESP | Letter to the SEC | Feb 26, 2018 | — |
| EFFECT | Filing | Feb 23, 2018 | — |
| EFFECT | Filing | Feb 23, 2018 | — |
| CORRESP | Letter to the SEC | Oct 3, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 28, 2017 | — |
| PRER14A | Preliminary proxy statement | Sep 27, 2017 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2017 | — |
| D | Filing | Sep 25, 2017 | — |
| EFFECT | Filing | Mar 22, 2017 | — |
| UPLOAD | Letter from the SEC | Mar 21, 2017 | — |
| CORRESP | Letter to the SEC | Mar 20, 2017 | — |
| EFFECT | Filing | Feb 27, 2017 | — |
| CORRESP | Letter to the SEC | Feb 23, 2017 | — |
| UPLOAD | Letter from the SEC | Feb 22, 2017 | — |
| EFFECT | Filing | Jan 13, 2017 | — |
| EFFECT | Filing | Jan 13, 2017 | — |
| EFFECT | Filing | Jul 14, 2016 | — |
| CORRESP | Letter to the SEC | Jul 12, 2016 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2016 | — |
| 25-NSE | Delisting notice | Jun 13, 2016 | — |
| CT ORDER | Filing | May 16, 2016 | — |
| EFFECT | Filing | May 12, 2016 | — |
| CORRESP | Letter to the SEC | May 12, 2016 | — |
| CORRESP | Letter to the SEC | May 12, 2016 | — |
| CERTNAS | Auto-generated paper document | May 11, 2016 | — |
| 8-A12B/A | Amendment no. 1 to form 8-a | May 11, 2016 | — |
| CERTNAS | Auto-generated paper document | May 5, 2016 | — |
| CORRESP | Letter to the SEC | May 5, 2016 | — |
| CORRESP | Letter to the SEC | May 5, 2016 | — |
| CORRESP | Letter to the SEC | May 4, 2016 | — |
| CORRESP | Letter to the SEC | May 4, 2016 | — |
| 8-A12B | Form 8-a12b | Apr 29, 2016 | — |
| CORRESP | Letter to the SEC | Apr 27, 2016 | — |
| UPLOAD | Letter from the SEC | Feb 26, 2016 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2016 | — |
| CORRESP | Letter to the SEC | Jan 15, 2016 | — |
| DRS/A | Filing | Jan 5, 2016 | — |
| UPLOAD | Letter from the SEC | Dec 30, 2015 | — |
| D | Filing | Dec 23, 2015 | — |
| DRSLTR | Filing | Dec 18, 2015 | — |
| DRS/A | Filing | Dec 18, 2015 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2015 | — |
| DRS | Filing | Nov 16, 2015 | — |
| D | Filing | Oct 13, 2015 | — |
| D | Filing | Aug 10, 2015 | — |
Showing 100 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- OTLK (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Iselin, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1649989
- Former names
- Oncobiologics, Inc. (until Nov 13, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.